Sol-Gel Technologies

Sol-Gel Technologies is a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Its current product candidate pipeline consists of late-stage branded product candidates that leverage its proprietary silica-based microencapsulation technology platform, and several generic product candidates across multiple indications. Sol-Gel was successful in developing pioneer topical drugs, Twyneo and Epsolay, for the treatment of acne and inflammatory lesions of rosacea. Both products are marketed in the US by Galderma since 2022. The company is developing topical patidegib that is expected to be approved for the treatment of Gorlin syndrome and topical erlotinib for the treatment of pachyonychia congenita and other rare skin indications.

Sol-Gel Technologies has raised $146M in total funding across 7 rounds. The company is currently at the Public stage. Key investors include Medica Venture Partners, JVP, Argonaut Ventures.

Sol-Gel Technologies was founded in 1997 by Alon Seri-Levy, Dr. (Co-Founder & CEO).

Sol-Gel Technologies operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drug Delivery, Drugs Discovery & Development, with core technologies in Materials & Substances, Nanomaterials, Biologicals. Target customers: Healthcare & Life Sciences, Life Sciences, Pharmaceuticals.

Sol-Gel Technologies is based in Golda Meir Street 7, Nes Ziyyona, Israel, Center District.